These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 32544304)
1. COVID-19 research: an opinion piece. Waters L; Rockstroh JK HIV Med; 2020 Sep; 21(8):536-540. PubMed ID: 32544304 [TBL] [Abstract][Full Text] [Related]
2. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19. Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798 [No Abstract] [Full Text] [Related]
3. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468 [TBL] [Abstract][Full Text] [Related]
6. Some drugs for COVID-19. Med Lett Drugs Ther; 2020 Apr; 62(1595):49-50. PubMed ID: 32324177 [No Abstract] [Full Text] [Related]
7. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Giovane RA; Rezai S; Cleland E; Henderson CE Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275 [TBL] [Abstract][Full Text] [Related]
8. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19. Oldenburg CE; Doan T Am J Trop Med Hyg; 2020 Jun; 102(6):1154-1155. PubMed ID: 32297590 [No Abstract] [Full Text] [Related]
9. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. Lima WG; Brito JCM; Overhage J; Nizer WSDC Arch Virol; 2020 Aug; 165(8):1729-1737. PubMed ID: 32514689 [TBL] [Abstract][Full Text] [Related]
10. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Martinez MA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies. Al-Tawfiq JA; Memish ZA Int J Antimicrob Agents; 2020 May; 55(5):105968. PubMed ID: 32259576 [TBL] [Abstract][Full Text] [Related]
13. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Cingolani A; Tummolo AM; Montemurro G; Gremese E; Larosa L; Cipriani MC; Pasciuto G; Liperoti R; Murri R; Pirronti T; Cauda R; Fantoni M; Infection; 2020 Oct; 48(5):767-771. PubMed ID: 32642806 [TBL] [Abstract][Full Text] [Related]
14. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831 [TBL] [Abstract][Full Text] [Related]
15. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672 [TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic agents against COVID-19: What we know so far. Lu CC; Chen MY; Lee WS; Chang YL J Chin Med Assoc; 2020 Jun; 83(6):534-536. PubMed ID: 32243270 [TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? Owa AB; Owa OT J Microbiol Immunol Infect; 2020 Oct; 53(5):674-675. PubMed ID: 32474026 [TBL] [Abstract][Full Text] [Related]
19. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982 [TBL] [Abstract][Full Text] [Related]
20. Treatment options for COVID-19: The reality and challenges. Jean SS; Lee PI; Hsueh PR J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]